# Fred Hutchinson Cancer Center: Phase 2 study started recruiting, 27 planned (Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Fred Hutchinson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer |
| NCT ID | NCT07667335 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma |
| Intervention types | drug, procedure, biological |
| Target enrollment | 27 |
| Site countries | United States |
| Posted | 2026-06-25 |
| Planned start | 2026-10-20 |
| Event | Started recruiting |
| Event date | 2026-10-20 |
| Last update posted | 2026-10-22 |

## Why this score
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07667335). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.